The IBEC is set to lead the coordination of the PHOTOTHERAPORT project, which will be developed with funding from the European Innovation Council’s Pathfinder Open programme. The project focuses on the development of luminescent implants and light-activated drugs for innovative neuromodulation therapies. PHOTOTHERAPORT will comprise an international consortium of 8 institutions and will receive €3 million over 3 years for the preclinical study of these implants.
IBEC researchers have revealed the role played by the cellular prion protein (PrPC) – which is associated with a plethora of biological functions including cell proliferation, differentiation and signaling – in epilepsy.
In the latest edition of Scientific Reports, a Nature group journal, the Molecular and Cellular Neurobiotechnology group and their collaborators outline findings that could lead to a better understanding of rapid neurodegenerative diseases that involve epileptic fits, such as Creutzfeldt-Jacob disease (CJD).